Adaptive Biotechnologies (ADPT) Asset Writedowns and Impairment (2025 - 2026)

Adaptive Biotechnologies (ADPT) posted Asset Writedowns and Impairment of $347000.0 for Q1 2026, down 38.37% sequentially from $563000.0 in Q4 2025.

Adaptive Biotechnologies (ADPT) Asset Writedowns and Impairment (2025 - 2026) Analysis & Trends

Adaptive Biotechnologies has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $347000.0 in Q1 2026.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $347000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $910000.0 (changed N/A YoY) and the FY2025 annual result came in at $563000.0, down 92.19% from the prior year.
Asset Writedowns and Impairment slipped to $347000.0 in Q1 2026 per ADPT's latest filing, from $563000.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $563000.0 in Q4 2025 and troughed at $347000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Thermo Fisher Scientific	213.88 Bn	209.81 Bn	8.34 Bn
2	Danaher	140.65 Bn	136.30 Bn	3.61 Bn
3	Idexx Laboratories	46.02 Bn	45.83 Bn	779.09 Mn
4	Agilent Technologies	39.85 Bn	38.05 Bn	990.00 Mn
5	Iqvia Holdings	39.20 Bn	37.12 Bn	1.44 Bn
6	Natera	38.80 Bn	37.70 Bn	696.04 Mn
7	Illumina	30.11 Bn	28.94 Bn	770.00 Mn
8	Mettler Toledo International	28.66 Bn	28.61 Bn	650.22 Mn
9	Quest Diagnostics	26.24 Bn	25.61 Bn	1.03 Bn
10	Adaptive Biotechnologies	3.80 Bn	3.58 Bn	52.17 Mn

Download Data